×
+ All Categories
Log in
English
Français
Español
Deutsch
The top documents of office-of-health-economics
Towse ISPOR Incoming President's Remarks
1.597 views
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
589 views
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
2.144 views
Adrian Towse Presentation - Affordability
612 views
Structured decision making approaches to the inclusion of multiple criteria in HTA
667 views
Dimensions of value, assessment, and decision making
714 views
Health economic evaluation throughout the ages
225 views
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 March 2016 Jorge Mestre-Ferrandiz
1.082 views
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Leap in the Dark?
1.224 views
Personalised Medicine in the EU— Evolving Landscape and New HTA Considerations
98 views
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potential for PBRSAs
588 views
The economics of medical research: Public/private spillovers and the rate of return
195 views
OHE Lunchtime Seminar:Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development: Current and Future Perspectives and Challenges
66 views
“Multi-indication Pricing: Do we want it? Can we operationalize it?”
544 views
Perspective, priorities and plurality
414 views
Age, utilities, and self-reported health: issues for HTA
414 views
Marketing Authorisations in the EU: The Centralised Procedure
212 views
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to Maximise Value
491 views
Preferences for an End of Life 'Premium‘: An Examination of Framing Effects and Study Design Considerations
223 views
EQ-5D - 3L or 5L?
200 views
Next >